MktsMarkets

Artelo Biosciences, Inc.
NASDAQ: ARTLKey statistics
ARTL News
Stories mentioning ARTL from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 773.00 | 893.00 | 1,275 | 1,871 | 1,384 | 2,476 | 325.00 | 1,685 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,689 | 2,786 | 3,089 | 3,150 | 2,379 | 3,812 | 1,195 | 2,512 |
| Operating Income (Loss) | (2,689) | (2,786) | (3,089) | (3,150) | (2,379) | (3,812) | (1,195) | (2,512) |
| Interest Income | ||||||||
| Interest Expense | 100.00 | 11.00 | 111.00 | 72.00 | 0.00 | 0.00 | 0.00 | |
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income (Loss) | (2,958) | (4,166) | (3,120) | (3,221) | (2,372) | (3,778) | (1,132) | (2,433) |
| Earnings Per Share (Basic) | ||||||||
| Earnings Per Share (Diluted) | (4.00) | (4.05) | (3.97) | (5.61) | (12.55) | (7.04) | (2.10) | (4.52) |
| Weighted Average Shares Outstanding (Basic) | ||||||||
| Weighted Average Shares Outstanding (Diluted) | 739.00 | 1,029 | 787.00 | 574.00 | 189.00 | 537.00 | 538.00 | 538.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ARTL
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a stock listed on the Nasdaq Stock Market under the ticker symbol ARTL. It last traded at $1.50 (Nov 18, 2026, 4:00 PM ET), down 10.7% on the day. That gives Artelo Biosciences a market capitalisation of $1.4M.
Over the past 52 weeks ARTL has traded between $1.61 and $179.19.
For the quarter ended Mar 31, 2026 it reported a net loss of $3.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$3.0M |
| Dec 31, 2025 | — | -$4.2M |
| Sep 30, 2025 | — | -$3.1M |
| Jun 30, 2025 | — | -$3.2M |
From Artelo Biosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…